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ABSTRACT
Background and the purpose of the study: Human fibroblast growth factor 20 (FGF20) is a 16.5 
kDa protein containing 154 amino acid residues with reportedly poor thermal stability, and low 
stability, which are considered to be major factors that can limit its pharmacological applications. 
Thus, the aim of this study was to enhance the thermal stability and bio activity of a therapeutic 
FGF20 by addition of sucrose or heparin as additives and also at different temperatures. 
Methods: A variety of biophysical techniques such as far-UV circular dichroism (CD), 
fluorescence and high resolution derivative UV absorption spectroscopy, were employed to 
characterize FGF20 and study the effects of heparin and sucrose on its thermal stability and bio 
activity at pH 7.0. 
Results: Results of this study suggest that human FGF20 is significantly unstable and induction of 
heat by increased temperatures results in aggregation and precipitation at pH 7.0. Great changes 
in the fluorescence intensity and shape were achieved by addition of heparin and sucrose at 
different temperatures compared to the control. From 10 °C to 60 °C, no significant changes 
were observed in far-UV CD spectrum compared to the control, but significant changes were 
observed by adding sucrose when these temperatures are above 45 °C. Upon addition of heparin 
and sucrose, the mitogenic activity increased significantly at all tested temperatures, and these 
changes may be related to the roles of heparin and sucrose on the structure and conformation 
of FGF20.
Conclusion: Results of this study suggest that heparin and sucrose as additives seems to benjm  
sufficient to prevent thermal inactivation of FGF20 and also maintain its conformation stability 
and bio activity. 
Keywords:  Human  fibroblast  growth  factor  20,  Thermal  stability,  Circular  dichroism, 
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INTRODUCTION
Fibroblast growth factors (FGFs) constitute a 
family of heparin binding proteins involved in the 
regulation of cell growth and differentiation, and 
angiogenesis (1). FGF20 is a member of this family 
that is expressed preferentially in dopaminergic 
neurons of the substantia nigra pars compacta 
(SNPC) of rat brain and also expressed in human 
cerebellum and SN tissue (2). Evidences have 
suggested that the expression of FGF20 significantly 
enhances the survival of midbrain dopaminergic 
neurons, and monkey stem cells are differentiated 
in vitro into dopaminergic neurons after treatment 
with exogenous FGF20. In addition, FGF20 have 
been transplanted into a primate Parkinson’s disease 
model, alleviated some symptoms (3, 4).Therapeutic 
potential of FGF20 has also been investigated for 
the  treatment  of  acute  intestinal  inflammation, 
parkinson’s disease susceptibility and alleviating 
oral mucositis (5, 6). 
Recently, recombinant technology has been utilized 
to produce growth factor drugs massively. However, 
a major problem in the utilization of these peptides 
is their thermal stability and enhanced thermal 
stability is a desirable feature for therapeutic uses of 
wound healing and tissue repair. Several members 
of FGF family have been shown to exhibit marginal 
stability with disrupted secondary and tertiary 
structure under physiological conditions (7). Earlier 
results suggested that heparin and sugar lock the 
molecules in their native conformations and protect 
them from thermal unfolding in some growth factors 
(8, 9). FGF20 is a potent mitogen and angiogenic 
factor, with reportedly poor thermal stability and a 
relatively short in vivo half-life (10). The present 
work was conducted to study the effects of heparin 
138and sucrose on the thermal stability and activity 
of FGF20 using high resolution UV absorption 
spectroscopy,  intrinsic  and  extrinsic  fluorescence 
spectroscopy, and far-UV circular dichroism (CD) 
spectroscopy. 
MATERIAL AND METHODS
Chemicals and protein purification
Heparin sodium and sucrose were purchased from 
Sigma (St. Louis, USA). Chemicals were analytical 
grade. All solutions were made in Milli Q water. 
A synthetic gene for the 140 amino acid form of 
human acidic fibroblast growth factor was inserted 
into the pET-32a(+) vector (Novagen, Madison, WI, 
USA) and introduced into Escherichia  coli  strain 
BL21(DE3). The transformed E. coli was grown at 
37°C in Lysogeny broth (LB) media to an optical 
density of A600 = 1.0. At this point 1 mM of isopropyl 
α-D-thiogalactopyranoside (IPTG) was added and 
the incubation temperature was shifted to 28 °C. 
The cells allowed to grow for an additional 4 hrs and 
were then harvested by centrifugation (10000 rpm) 
for 10 min and stored frozen (-20 °C) prior to use. 
Protein  was  purified  to  apparent  homogeneity,  as 
judged by Coomassie Brilliant Blue-stained sodium 
dodecyl sulfate polyacrylamide gel-electrophoresis 
(SDS-PAGE), by a combination of Ni-NTA column 
and heparin affinity chromatography using AKTA 
Explorer system (Amersham Biosciences, Uppsala, 
Sweden). Protein purity of >95% was confirmed by 
silver-stained SDS-PAGE and high performance 
liquid chromatography (HPLC, Agilent 1100, 
Agilent Technologies, Palo Alto, CA, USA). The 
stock human FGF20 samples were dialyzed against 
10 mM phosphate/10 mM citrate buffer containing 
200 mM sodium sulfate at pH 7.0. The samples were 
filtered  through  a  0.23  μm  filter  (Whatman  Ltd., 
Maidstone, United Kingdom) to remove insoluble 
aggregates and stored at -80  °C for analyses. 
Samples were diluted to final concentrations of 0.2 
mg/ml. Protein concentration was determined using 
an experimentally determined extinction coefficient 
(E0.1% 1cm) of 0.97 at 280 nm.
Assay of FGF20 activity
The mitogenic activity of FGF20 was assessed by 
methylthiazoletetrazolium (MTT) assay using NIH 
3T3 cells (11). Viable cells were assessed through 
colorimetric changes using a Model 550 microplate 
reader at 570 and 630 nm (Bio-Rad, Cambridge, 
MA, USA). 
Turbidity measurement
UV absorbance spectra of FGF20 were collected 
as a function of temperature from 10 to 60 °C 
with a Beckman Coulter DU800 UV-visible 
spectrophotometer (Beckman Coulter Inc., Fullerton, 
USA) at 2.5 °C interval. 
Fluorescence spectroscopy
Fluorescence spectra of human FGF20 were 
obtained  via  F-7000  spectrofluorometer  (Hitachi 
High-Technologies, Tokyo, Japan), equipped with 
a temperature controlled cell sample holder. For 
extrinsic ANS fluorescence experiments, an optimal 
molar ratio of 15:1 (ANS: protein) was used. Both 
Trp  and ANS  fluorescence  emission  spectra  were 
collected from 10 to 60 °C at 5 °C intervals with a 5 
min equilibration time at each temperature point. 
Circular dichroism spectroscopy
Far-UV CD studies were performed with an 
AVIV model 400 spectrometer (AVIV Associates, 
Lakewood, NJ, USA). All spectra were corrected 
by subtracting the baseline and the data were 
expressed  as  mean  residue  ellipticity,  [θ],  which 
was given the units of [deg·cm2·dmol-1]. The CD 
signals were monitored as a function of temperature 
from 10 to 60 °C at 5 °C intervals for samples at 
pH 7.0, with a resolution of 0.2 °C and a heating 
rate of 20 °C per min. Quantitative estimations of 
the secondary structure content were made with 
the aid of the programs CDSSTR, CONTIN and 
SELCON3  included  in  the  CDPro  software  package                
(http://lamar.colostate.edu/~sreeram/CDPro) (12).  
Effects  of  heparin  and  sucrose  on  CD  and 
fluorescence spectroscopy 
In this experiment, heparin used at a concentration 
of 4-fold weight excess (solute: protein, w/w), and 
sucrose was used at a concentration of 50-fold 
weight excess in a pH 7.0, 100 mM phosphate 
buffer. FGF20 concentration of 0.2 mg/ml was used 
for all the experiments described below. The same 
instrument and experimental procedure that are 
described above were used for CD and fluorescence 
spectroscopy analysis. 
RESULTS AND DISCUSSION
Effects of different temperatures on aggregation of 
FGF20
The optical density of human FGF20 solutions 
at 350 nm (OD350) was measured to monitor the 
protein’s aggregation behavior induced by increasing 
temperature (Fig. 1). Increases of optical density at 
high temperatures may be related to the increased 
particle size due to aggregation, while a later drop in 
the signal reflects gross settling of the protein above 
55 °C.
Effects of different temperatures and additives on 
fluorescence spectrum of FGF20
Changes  in  fluorescence  spectra  at  different 
temperatures and additives are shown in figures 2 
and 3. A single trp of FGF20 showed fluorescence 
spectrum with λmax at 337 nm indicating trp residue 
in  the  hydrophobic  environment. The  λmax  was 
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gradually blue shifted by increasing temperatures 
compared to the control (Fig. 2). The blue shift in 
tryptophan fluorescence probably reflects occupying 
a less polar environment within the protein, and is 
corrected with the changes of secondary structure 
components  (Fig.  4).  The  fluorescence  emission 
by addition of heparin had a very low quantum 
yield,  and  the  fluorescence  intensity  decreased 
significantly by increase in temperature up to 60 °C 
(Fig. 3A). These decreases may partly results from 
the conformation changes of active center in the 
FGF20 molecule. In addition, the λmax showed a 
small red-shift to 331 nm, and maintained a stable 
value up to 40 °C, and then showed a small blue shift 
(2 or 4 nm) by increase in temperatures up 60 °C in 
comparison to the control. Upon addition of sucrose, 
the  fluorescence  intensity  was  about  0.03  times 
of those without additive, and the emission λmax 
showed red shift from 2 to 6 nm compared to the 
control (Figs. 2 and 3B). Fluorescence quenching 
may be explained by occurrence of interaction 
between sucrose and conformation center of 
tryptophan in the molecule. These results indicate 
that addition of heparin and sucrose may change 
the micro-environment conformation of trp center 
and decrease the fluorescence intensities of FGF20 
significantly, but they showed different effects.
Effects of different temperatures and additives far-
UV CD spectra of FGF20
Results of far-UV CD spectra exhibited features 
typical for proteins containing b-trefoil structure, 
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Figure  1.  Derivative of UV absorbance spectroscopy. Optical densities at 350 nm 
(OD350) are recorded from 10 to 60 °C for FGF20 at pH 7.0. 
Figure 1. Derivative of UV absorbance spectroscopy. Optical densities at 350 nm (OD350) are recorded from 10 to 60 °C for FGF20 at 
pH 7.0.
Figure 2. Intrinsic fluorescence of human FGF20 from 10 to 60 °C at pH 7.0. The excitation wavelength is set at 295 nm.
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Figure 2. Intrinsic fluorescence of human FGF20 from 10 to 60 °C at pH 7.0. The 
excitation wavelength is set at 295 nm.   
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and CD curves manifest a positive peak at 227 nm 
and a negative signal near 207 nm, which clearly 
indicates  a  mixed  α-helix  and  b-trefoil  structure 
(Patterns are no shown). These results are consistent 
with pervious reports and appear to be a common 
feature of the FGF family (13, 14). The relative 
percentages of secondary structure elements were 
analyzed using CDPro package (Table 1), and results 
suggest that values of 13.9% α-helix, 37.2% β-sheet, 
22.4% β-turn, and 48.8% random coil are calculated 
at 10 °C. This protein showed slight variations in the 
percentage of calculated secondary structure from 
10 to 45 °C, such as increased values of α-helix 
as  well  as  reduced  values  of  β-sheet,  β-turn  and 
random coil. However, the percentage of random 
coil increased significantly at temperatures higher 
than 50 °C which indicate a gradually unfolding 
process of this protein above 45 °C. As shown in 
figure 4A, strong negative peaks with a minimum 
at 213 nm and weak positive peaks at 227 nm in 
far-UV CD spectrum of FGF20 were detected 
by addition of heparin. In addition, no significant 
change was observed by increase in temperatures 
compared to that of the addition of heparin at 10°C. 
These strong negative peaks at 213 nm presented 
a much higher content of α-helical. Upon addition 
of heparin, the structure calculations indicated that 
this protein was formed by 34.6% α-helix, 16.8% 
β-sheet,  17.2%  β-turns,  and  29%  random  coil  at 
pH 7.0 and 10 °C. Addition of additives resulted 
in significant increase in values of α-helix, reduced 
values  of  β-sheet,  β-turns  and  random  compared 
to those without additives (Table 1). These results 
suggest that conformational transition from β-sheet, 
Figure 3. Effects of heparin and sucrose on the fluorescence spectra of FGF20 from 10 to 60 °C at pH 7.0. A: 4-fold weight excess of 
heparin. B: 50-fold weight excess of sucrose.
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β-turns  and  random  coil  to  α-helix  structure  was 
observed when heparin was added as a stabilizing 
reagent during unfolding process. Figure 4B shows 
changes in far-UV CD spectrum of FGF20 from 
10 °C to 60 °C upon addition of sucrose. Results 
suggest that no significant change were observed 
when these temperatures are below 45 °C compared 
to that of the addition of sucrose at 10°C. However, 
spectrum  shows  significant  changes  when  the 
temperatures are higher than 60 °C. Upon addition 
of sucrose, the percentages of the secondary 
structures  were  calculated  to  be  20.8%  α-helix, 
26.3% β-sheet, 20.2% β-turns, and 39.9% random 
coil at 10 °C, indicating that the addition of sucrose 
may increase the percentage of α-helix structure by 
reducing some percentages of β-sheet, β-turns and 
random coil structure compared to those without 
additives.  Moreover,  the  percentages  of  α-helix 
structure at different temperatures were higher 
than those without additives, and the percentages 
of β-sheet, β-turns and random coil were less than 
those without additive. Based on these results, it may 
suggested that part of secondary structure elements 
in the FGF20 molecules, like β-sheet, β-turns and 
random coil, may transform to α-helix upon addition 
of heparin and sucrose. Thus, these conformational 
transitions may maintain the structure stability and 
activity of FGF20 (Figs 4 and 5). Earlier results 
have shown that heparin and sucrose are required 
to control and maintain the stability of FGF family 
proteins (13, 15). In addition, studies also show that 
the presence of heparin in the solution has a much 
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Figure 4. Effects of heparin and sucrose on the CD spectra of FGF20 at pH 7.0. A: a 
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Figure 4. Effects of heparin and sucrose on the CD spectra of FGF20 at pH 7.0.
A: a 4-fold weight excess of heparin
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greater stabilizing effects than that of sucrose.
Effects of different temperatures and additives on 
mitogenic activity of FGF20
Results suggest that the activity of FGF20 gradually 
decrease by increase in temperature up to 60 °C. 
A complete loss of the mitogenic activity was 
observed at 60 °C for 5 min. In contrast, the activity 
was  significantly  enhanced  when  heparin  was 
added in the solution before increase in temperature 
compared to those without additives. Thus, the 
highest activity was observed between 3.46 and 3.6 
Structures 10°C 15°C 20°C 25°C 30°C 35°C 40°C 45°C 50°C 55°C 60°C
No additive
α-helix 13.9 13.9 14.5 14.5 15.2 14.9 15.3 15.4 14.1 14 13.9
β-sheet 37.2 37.3 36.3 36.1 34.9 35.4 34.6 34.3 36.7 36.9 37.1
β-turn 22.4 22.4 22.1 22.1 21.8 21.9 21.6 21.5 21.9 21.9 21.9
Random Coil 48.8 48.7 48.4 48.1 47.8 47.8 47.7 47.6 50.4 50.6 51.2
Heparin
α-helix 34.6 34.6 34 33.9 33.3 33.9 33.9 34.7 35.2 35.4 39
β-sheet 16.8 16.8 17.2 17.2 17.5 17.3 17.2 16.7 16.5 16.3 14.5
β-turn 17.2 17.2 17.4 17.4 17.5 17.5 17.3 17.3 17 17 16.4
Random Coil 29 29 28.9 29 29.2 28.8 29.4 28 29 28.4 26
Sucrose
α-helix 20.8 20.3 20.8 20.1 19.6 21 20.6 19.4 17.8 18.9 18.3
β-sheet 26.3 27.9 27.2 28.2 28.7 27.1 27.3 28.8 30.5 29.4 30.1
β-turn 20.2 20.4 20.3 20.4 20.6 20.2 20.1 20.5 20.7 20.3 20.6
Random Coil 39.9 40.2 38.9 40.7 40.7 39.7 40.7 41.9 44.4 44 44
Table 1. Analysis of secondary structure (%) of CD Spectrum of FGF20 at various temperatures and in the presence of additives.
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Figure 5. Effects of different temperatures and additives on the mitogenic activity of 
FGF20 at pH 7.0. Values are average of three independent determinations. Full (100%) 
activity corresponds to the protein concentration of 0.2 mg/ml. 
 
Figure 5. Effects of different temperatures and additives on the mitogenic activity of FGF20 at pH 7.0. Values are average of three inde-
pendent determinations. Full (100%) activity corresponds to the protein concentration of 0.2 mg/ml.
times  of  the  control  when  the  temperature  was  below                              
35 °C. However, the activity decreased gradually by 
increase in temperature up to 60 °C. These results 
suggest that heparin binding sites might locate in the 
activity site (7, 13, 15). Although addition of sucrose 
may increase the activity of FGF20, its stabilizing 
effects of sucrose on the activity were lower than 
those which were formed by addition of heparin. 
FGF has been shown to possess structurally localized 
heparin and polyanion binding sites on its surface. It 
has been reported that heparin binding has significant Effects of temperature and additives on stability and spectrum 144
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effects on the biological activity of the protein and 
provides dramatic thermal stabilization (7). In 
conclusion, the present findings suggest that heparin 
and sucrose play important roles in maintenance of 
the conformation and activity of FGF20.
It seems that addition of stabilizers might be 
useful for the formulation design of therapeutic 
proteins.